Sagimet Biosciences Reports Third Quarter 2024 Financial Results and Provides Corporate Updates
Provided By GlobeNewswire
Last update: Nov 14, 2024
Denifanstat received Breakthrough Therapy designation from FDA for MASH
Results from Phase 2b FASCINATE-2 study of denifanstat published in The Lancet Gastroenterology & Hepatology
Read more at globenewswire.comNASDAQ:SGMT (12/19/2025, 2:51:40 PM)
6.09
+0.13 (+2.18%)
Find more stocks in the Stock Screener
